Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent advances in primary CNS lymphoma.

Khê Hoang-Xuan1, Sophie Camilleri-Broët, Carole Soussain

  • 1Department of Neurology, Groupe Hospitalier Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, Paris 75651 Cedex 13, France. khe.hoang-xuan@psl.ap-hop-paris.fr

Current Opinion in Oncology
|January 1, 2005
PubMed
Summary

High-dose methotrexate (MTX)-based chemotherapy with deferred radiotherapy offers effective treatment for primary CNS lymphoma (PCNSL) while preserving neurocognition. This approach is particularly beneficial for elderly patients, improving quality of life.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intensified Rituximab, Methotrexate, Procarbazine, and Cytarabine (R-MPVA) Regimen With Sequential Addition of Etoposide to R-MPV and Ifosfamide to R-AraC for Newly Diagnosed Primary CNS Lymphoma Patients Aged Between 60 and 70 Years: An LOC Network Study.

Hematological oncology·2026
Same author

Radiological and FDG-PET imaging features of Epstein-Barr virus-positive primary central nervous system lymphomas.

Journal of neurology·2026
Same author

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

CAR T-Cell Therapy in Patients With Primary Central Nervous System Lymphoma: A LOC Network Study.

American journal of hematology·2026
Same author

Prognostic factors in adult patients with medulloblastoma.

Neuro-oncology practice·2026

Area of Science:

  • Neuro-oncology
  • Hematology
  • Immunology

Background:

  • Primary CNS lymphoma (PCNSL) affects the brain, spinal cord, and meninges in immunocompetent individuals.
  • Standard treatment involves high-dose methotrexate (MTX)-based chemotherapy and radiotherapy, but carries risks of neurotoxicity.

Purpose of the Study:

  • To review recent advancements in understanding the pathogenesis and treatment of PCNSL in immunocompetent patients.
  • To evaluate current and emerging therapeutic strategies for PCNSL.

Main Methods:

  • Review of recent clinical trials and studies on PCNSL treatment.
  • Analysis of treatment outcomes, including efficacy and neurotoxicity.
  • Evaluation of novel therapeutic agents and treatment modalities.

Related Experiment Videos

Main Results:

  • High-dose MTX-based chemotherapy with deferred radiotherapy shows comparable efficacy to chemoradiotherapy with better neurocognitive preservation.
  • Intensive chemotherapy with autologous stem cell transplantation is promising for relapsed/refractory PCNSL but its first-line role is uncertain.
  • New agents like temozolomide, topotecan, and intrathecal rituximab show modest activity in relapsed PCNSL and are candidates for new regimens.

Conclusions:

  • MTX-based chemotherapy is the preferred approach for elderly PCNSL patients, balancing tumor control and quality of life.
  • Future research should investigate radiotherapy's role as consolidation in younger patients and evaluate intensive chemotherapy and new drug combinations.